I-Corps Proposal for Commercialization of Live Cell Assays to Identify and Interrogate Stressed Neurons in Models of Neurodegenerative Disease

Information

  • Research Project
  • 9856752
  • ApplicationId
    9856752
  • Core Project Number
    R43NS108817
  • Full Project Number
    3R43NS108817-01S1
  • Serial Number
    108817
  • FOA Number
    PA-19-029
  • Sub Project Id
  • Project Start Date
    4/29/2019 - 5 years ago
  • Project End Date
    6/18/2019 - 5 years ago
  • Program Officer Name
    FERTIG, STEPHANIE
  • Budget Start Date
    4/29/2019 - 5 years ago
  • Budget End Date
    6/18/2019 - 5 years ago
  • Fiscal Year
    2019
  • Support Year
    01
  • Suffix
    S1
  • Award Notice Date
    4/5/2019 - 5 years ago
Organizations

I-Corps Proposal for Commercialization of Live Cell Assays to Identify and Interrogate Stressed Neurons in Models of Neurodegenerative Disease

SUMMARY/ABSTRACT The goal of our predicate SBIR Phase I award is to develop genetically-encoded fluorescent assays to detect cell stress in models of neurodegeneration. Typically this degeneration is studied by counting dead cells, in animal or cellular models of the disease, which is an insensitive measurement of chronic, slow, cellular stress. Our goal is to create genetically encoded, fluorescent biosensors that light up living, stressed cells long before they are destined to die, giving scientists sensitive new tools to identify and potentially rescue stressed neurons. Our aim is to create cell stress based assays that can be adopted into neurodegenerative research and drug development platforms. To successfully bring these assays to market a thorough understanding of the customer?s unmet needs are crucial. The I-Corps program will provide unique training and customer interactions that will greatly enhance our ability to successfully bring these products to market. Our current strategies for commercialization will be focused on developing multiple platforms for assay deployment. For example, the assay will be delivered in viral vectors as well as made available for stable cell line production and integration into animal models of neurodegeneration. The I-Corps program would grant us a deeper understanding of our current marketplace, the needs of our customers, and strategies to implement our commercialization plan. Upon completion of the I-Corps program our commercialization strategy will be reevaluated and modified based on customer feedback and strategies learned during the program.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R43
  • Administering IC
    NS
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    55000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:55000\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
  • Study Section Name
  • Organization Name
    MONTANA MOLECULAR, LLC
  • Organization Department
  • Organization DUNS
    145280157
  • Organization City
    BOZEMAN
  • Organization State
    MT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    597158250
  • Organization District
    UNITED STATES